ABSTRACT Introduction: The aim of this meta-analysis was to assess the effect of ongoing statin treatment on susceptibility to influenza virus infection and on influenza-associated mortality. Material and methods: Studies investigating the impact of statin treatment on influenza prevalence and mortality were searched in PubMed-Medline, Scopus, ISI Web of Knowledge, Embase, Proquest, OVID, EBSCO and CINAHLdatabases (up to June 30, 2020). Fixed- and random-effects model and generic inverse variance method were used for quantitative data synthesis. Results: In the meta-analysis of 15 arms of 3 eligible studies including flu-vaccinated and unvaccinated patients, treatment with statins was associated with a reduction of influenza virus prevalence [Odds Ratio (OR) 0.85, 95% Confidence Interval (CI) 0.73-0.99; p 0.040]. No significant effect of statins on the susceptibility to influenza infection was observed in the distinct communities of either vaccinated or unvaccinated subjects. Among 9 arms of 6 eligible studies, the use of statins among patients with influenza was associated with a reduced mortality [OR (95% CI), 0.68 (0.56, 0.82); p<0.001]. This result was confirmed for both 30-day mortality since influenza infection diagnosis [OR (95% CI), 0.61 (0.47, 0.80); p<0.001] and for up to 90-day mortality [OR (95% CI), 0.74 (0.55, 1.00); p=0.042]. Conclusions: A reduced influenza prevalence and anincreased survivalfrom influenza infection was observed in patients on ongoing statin treatment. Further research is needed to define the possible role of statins as adjunctive therapy in patients with influenza infection. Submit your paper Archive Instructions for authors Article has an altmetric score of 10 Share Send by email RELATED ARTICLE Does prior SARS-CoV-2 infection increase the risk of adverse effects after mRNA vaccination (BNT162b2) - the retrospective cohort study of physicians. Cost-effectiveness analysis of COVID-19 vaccination in Poland Statins as anti-pyroptotic agents Influenza as an important factor causing increased risk of patients’ deaths, excessive morbidity and prolonged hospital stays Right ventricular dysfunction and pulmonary hypertension in COVID-19: a meta-analysis of prevalence and its association with clinical outcome
Effect of Statins on Prevalence and Mortality of Influenza Virus Infection: A Systematic Review and Meta-Analysis
Mannarino, Massimo;Bianconi, Vanessa;Pirro, Matteo;
2022
Abstract
ABSTRACT Introduction: The aim of this meta-analysis was to assess the effect of ongoing statin treatment on susceptibility to influenza virus infection and on influenza-associated mortality. Material and methods: Studies investigating the impact of statin treatment on influenza prevalence and mortality were searched in PubMed-Medline, Scopus, ISI Web of Knowledge, Embase, Proquest, OVID, EBSCO and CINAHLdatabases (up to June 30, 2020). Fixed- and random-effects model and generic inverse variance method were used for quantitative data synthesis. Results: In the meta-analysis of 15 arms of 3 eligible studies including flu-vaccinated and unvaccinated patients, treatment with statins was associated with a reduction of influenza virus prevalence [Odds Ratio (OR) 0.85, 95% Confidence Interval (CI) 0.73-0.99; p 0.040]. No significant effect of statins on the susceptibility to influenza infection was observed in the distinct communities of either vaccinated or unvaccinated subjects. Among 9 arms of 6 eligible studies, the use of statins among patients with influenza was associated with a reduced mortality [OR (95% CI), 0.68 (0.56, 0.82); p<0.001]. This result was confirmed for both 30-day mortality since influenza infection diagnosis [OR (95% CI), 0.61 (0.47, 0.80); p<0.001] and for up to 90-day mortality [OR (95% CI), 0.74 (0.55, 1.00); p=0.042]. Conclusions: A reduced influenza prevalence and anincreased survivalfrom influenza infection was observed in patients on ongoing statin treatment. Further research is needed to define the possible role of statins as adjunctive therapy in patients with influenza infection. Submit your paper Archive Instructions for authors Article has an altmetric score of 10 Share Send by email RELATED ARTICLE Does prior SARS-CoV-2 infection increase the risk of adverse effects after mRNA vaccination (BNT162b2) - the retrospective cohort study of physicians. Cost-effectiveness analysis of COVID-19 vaccination in Poland Statins as anti-pyroptotic agents Influenza as an important factor causing increased risk of patients’ deaths, excessive morbidity and prolonged hospital stays Right ventricular dysfunction and pulmonary hypertension in COVID-19: a meta-analysis of prevalence and its association with clinical outcomeI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
